We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
5 own
3 watching
Current Price
$0.51
$-0.05
(-8.44%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
13.74M
52-Week High
5.17
52-Week Low
0.45
Average Volume
0.02M
Dividend Yield
--
P/E Ratio
--
Market Capitalization13.74M
52-Week High5.17
52-Week Low0.45
Average Volume0.02M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women s health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
8 months ago
NEW YORK, March 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bright Health Group, Inc. (NYSE: BHG), First Solar, Inc. (NASDAQ: FSLR), Talis ...
PR Newswire
8 months ago
Final Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Talis Biomedical Corporation (TLIS) Final Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead...
Globe Newswire
8 months ago
SAN FRANCISCO, March 06, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS) investors with significant losses to submit your losses now. A securities class action has been filed concerning defendants representations during Talis Feb. 2021 initial public offering...
Business Wire
8 months ago
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Talis Biomedical Corporation (Talis Biomedical or the Company) (NASDAQ: TLIS) in the United States District Court for the Northern District of...
Business Wire
8 months ago
Robbins Geller Rudman & Dowd LLP announces that purchasers of Talis Biomedical Corporation (NASDAQ: TLIS) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the Registration Statement) issued in connection with Talis Biomedicals February 12...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0.51
$-0.05
(-8.44%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00